Lara Pillay is a corporate associate in the Boston office of Kirkland & Ellis LLP.
Experience
Representative Matters
Since joining Kirkland, Lara has been involved in the following representations:
Amicus Therapeutics in its pending $4.8 billion sale to BioMarin
Avidity Biosciences in its pending $12 billion sale to Novartis, and the related spin-off of its early-stage precision cardiology programs
Prior to joining Kirkland, Lara was involved in the following representations:
SiteOne Therapeutics in its acquisition by Eli Lilly for up to $1 billion
Evergreen Theragnostics in its sale to Lantheus for up to $1 billion
The special committee of the board of directors of R1 RCM in its sale to investment funds affiliated with TowerBrook Capital Partners and Clayton Dubilier & Rice for an enterprise value of $8.9 billion
EyeBio in its sale to Merck for $1.3 billion up front and up to $1.7 billion in future milestone payments
The special committee of the board of directors of EngageSmart in its $4 billion sale to Vista Equity Partners
Mirati Therapeutics in its sale to Bristol Myers Squibb for up to $5.8 billion
Intercept Pharmaceuticals in its sale to Alfasigma for approximately $800 million
